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Summary: Combined treatment with the angiotensin-converting enzyme
(ACE) inhibitor delapril and the diuretic indapamide prevented vascular dam-
age in vital organs of salt-loaded stroke-prone spontaneously hypertensive rats
(SHRsp). Whether the changes occurring after long-term hypertension could
also be modulated in large arteries was investigated. Two-month-old SHRsp
were salt loaded and treated with the drug regimen until they reached 50%
mortality or around midlife. In a first experiment, delapril (12 mg/kg) and
indapamide (1 mg/kg) were administered daily separately or in combination.
In the second dose-finding experiment, delapril (6, 3, 1.5 mg/kg) and indap-
amide (0.5, 0.25, 0.125 mg/kg) in decreasing dose combinations were ana-
lyzed. Ultrastructural, histomorphometric, and biochemical studies were per-
formed on the thoracic aorta. When compared with delapril (12 mg/kg) or
indapamide (1 mg/kg) administered individually for 5 months, the combina-
tion 12 + 1 mg/kg was able to prevent the increase in extracellular matrix
deposition observed in other treatment groups, as assessed by histomorphom-
etry or 4-OH-proline biochemical determination. In the second experiment, a
half-dose (delapril 6 mg/kg + indapamide 0.5 mg/kg) combination was simi-
larly effective in counteracting fibrosis, but the other doses progressively
failed. In the first experiment, the combination had a stabilizing effect on
hypertension and stimulated diuresis. In the second experiment, arterial blood
pressure values and sodium balance were not consistently affected by the
treatments that antagonized fibrosis (i.e., delapril 6 mg/kg + indapamide 0.5
mg/kg and, less efficiently, delapril 3 mg/kg + indapamide 0.25 mg/kg). These
results suggest that indapamide interacts with ACE inhibitors to limit aortic
fibrosis independent of any well-established mechanism. Key Words: An-
giotensin-converting enzyme inhibitors—Arteries—Diuretic agents—
Fibrosis—Hypertension—Stroke-prone spontaneously hypertensive rats.
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An important goal of anti-hypertensive therapy is the
preservation of arterial structural integrity (1). It is well
known that large arteries undergo extensive remodeling
during long-term hypertension, mainly consisting of ves-
sel wall thickening due to fibrosis. This process is
thought to result from the complex interaction between
endothelial cells, leukocytes, and smooth muscle cells
(2–4). In particular, arterial smooth muscle cells undergo
hypertrophy and increase their metabolic activity assum-
ing a “secretory phenotype.” Some of these structural
changes seem to be maintained even after reversal of the
hypertensive state, leading to the permanent alteration of
vessel wall architecture (5).
Drug treatments capable of lowering blood pressure
levels have been shown to antagonize the effects of hy-
pertension on large vessels (6). Generally, this result de-
pends on the efficiency of the anti-hypertensive treat-
ment in lowering blood pressure (1). Conversely,
complete normalization of blood pressure is infrequent in
medical practice (7), and even when hypertension is well
controlled the associated arterial changes are not fully
prevented or reversed (8,9). As an exception, angioten-
sin-converting enzyme (ACE) inhibitors have been pro-
posed to prevent fibrosis in the arterial wall independent
of the efficiency of blood pressure control (3). This effect
seems to result from the prevention of angiotensin II
synthesis in the vessel wall, whereby angiotensin II can
enhance endothelial permeability to plasma proteins,
neutrophil migration, smooth muscle cell growth, and
consequently extracellular matrix deposition (4).
Another factor recently addressed as putatively in-
volved in arterial wall fibrosis and damage is sodium
chloride intake. It is a classic although still disputed no-
tion that sodium chloride intake can alter blood pressure
leading to hypertension (10). However, several lines of
evidence suggest that sodium chloride may damage the
arterial wall directly apart from changes in blood pres-
sure (11). Such evidence is more straightforward in ani-
mal models, especially stroke-prone spontaneously hy-
pertensive rats (SHRsp), in which a high-sodium diet
was found to increase arterial wall thickness and
collagen deposition. Moreover, sodium chloride can
negatively influence the properties of anti-hyperten-
sive treatments, an effect that should be carefully evalu-
ated in monotherapies with thiazide diuretics or ACE
inhibitors (12,13).
We recently demonstrated that the thiazidelike diuretic
indapamide combined with the ACE inhibitor delapril
consistently extends lifespan, preserves renal functions,
and prevents heart hypertrophy without lowering arterial
blood pressure, increasing diuresis in salt-loaded SHRsp
(14,15). In a third experiment (16), we demonstrated that
saluresis induced by combined treatment did not justify
the protective effects found in salt-loaded SHRsp. Based
on our previous findings, we hypothesized that the pro-
tective effects of delapril + indapamide could be ex-
tended to the vessel wall of large arteries, independent of
the anti-hypertensive and diuretic effects of the com-
bined treatment. To this aim, we studied the thoracic
aorta of salt-loaded SHRsp with histomorphometric, ul-
trastructural, and biochemical techniques to determine
the changes in smooth muscle cells, elastic laminae, and
other extracellular matrix components, such as collagens
and proteoglycans, consequent to different indapamide
and delapril drug treatments.
METHODS
Animals and treatments
Male specific-pathogen-free SHRsp, 5–6 weeks old,
were purchased from Charles River Italia (Calco, Italy).
They were housed, two per cage, under controlled tem-
perature (23 ± 1°C), humidity (about 60%), and daylight
cycle (light from 7 AM to 7 PM). After 2–3 weeks, they
were fed a Japanese-similar sodium chloride–enriched
diet (Mucedola, Settimo Milanese, Italy) characterized
by high sodium (0.36% wt/wt) and low potassium
(0.72%) content and also lower protein amount (18%)
(17). A 1% sodium chloride solution replaced tap water
as their beverage. Two different experiments were de-
signed. In experiment 1, the effects of delapril 12
mg/kg/d (n  12) and indapamide 1 mg/kg/d (n  12)
administered separately were compared with those of
their combination (n  12). Drug-free salt-loaded rats
were also considered to evaluate diet-related effects (n
 17). In experiment 2, the minimal effective doses of
the combination able to counteract aortic remodeling in
salt-loaded SHRsp were determined by using three dif-
ferent groups of treatment: delapril 6 mg/kg/d + indap-
amide 0.5 mg/kg/d (n  10), delapril 3 mg/kg/d + in-
dapamide 0.25 mg/kg/d (n 10), delapril 1.5 mg/kg/d +
indapamide 0.125 mg/kg/d (n 10). Drug-free and salt-
loaded SHRsp (n 10) were also included in the second
experiment. In each experiment, drugs were dissolved
within the beverage (1% sodium chloride solution) and
administered orally by drinking, as described elsewhere
(14,16). To adjust drug concentration to changes in body
weight and fluid intake, the solutions were prepared
freshly three times a week.
Body weight, fluid intake, and diuresis were measured
twice a week over a 24-h period as previously described
(14,16). To avoid contamination of urinary samples, the
animals were housed in metabolic cages for 24 h. Natri-
uria was determined by measuring sodium concentration
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with a selective electrochemical detector (AVL988–4,
AVL LIST GMBH, Graz, Austria). Blood pressure mea-
surements were performed three times/week using the
tail cuff method (BP recorder, Ugo Basile, Comerio,
Italy). When 50% mortality was reached in a treatment
group, surviving animals were killed to study chronic
lesions. The other animals that did not reach 50% mor-
tality were killed at different time intervals (14,16). In
this paper, we focused on aortic wall remodeling.
The animals were killed under deep anesthesia with
ketamine hydrochloride (ketamine, Ketalar, Parke-Davis,
100 mg/kg intraperitoneally). Animals used for morphol-
ogy studies were transcardiacally perfused with 100 ml
of saline solution, followed by 100 ml of ice cold Zam-
boni fixative, as previously described (14,16). Aortic
samples from nonperfused animals were used for bio-
chemical analyses. All procedures were in agreement
with The guide for the care and use of laboratory ani-
mals (National Institutes of Health publication no. 85–
23, revised 1985) and approved by local authorities.
Tissue processing
Thoracic aorta fixed by perfusion was removed and
postfixed at 4°C for 24 additional hours in 2.5% glutar-
aldehyde in Tyrode solution, pH 7.2, containing 0.1%
toluidine blue to visualize glycosaminoglycans. The
samples were washed in Tyrode solution, postfixed with
1% osmium tetroxide for 2 h at room temperature, de-
hydrated in a graded ethanol series, and embedded in
spurr resin (Polysciences, Warrington, PA, U.S.A.).
Light and electron microscopy
Semithin true cross-sections (1–1.5 m thick) of each
fragment adjusted for vessel orientation were cut on a
Reichert-Jung ultramicrotome, collected on slides, flat-
tened, dried, and postpolymerized on a hot plate at
150°C. Differential staining of the aortic wall compo-
nents was obtained by processing sections with mala-
chite green and basic fuchsin solutions, giving green-
blue cells, violet-blue elastic fibers, and magenta
collagen fibers and soluble matrix (18). The sections
were observed under a Zeiss (Munich, Germany) Ax-
iophot light microscope and images at 157.5 × total mag-
nification were collected for the morphometric analysis.
Thin sections from the same cross-oriented samples were
collected on 200-mesh nickel grids, stained with uranyl
acetate and lead citrate or with tannic acid specific for
elastic fibers, and examined under a JEOL 1200EXII
electron microscope.
Histomorphometry
At least 12 images (comprehensive of the intima
through the adventitia) were evaluated from three differ-
ent aortic fragments of each animal using an automated
image analysis system, consisting of a personal computer
equipped with a frame grabber (Imascan Prism, Ima-
graph, Chelmsford, MA, U.S.A.), a scanner (Epson film-
scan 200), and image analysis software (Image Pro Plus,
Soft Imaging Software GmbH, Munster, Germany).
Sampled areas from each image selected between the
internal and external elastic lamina, corresponding to the
tunica media, were digitized by scanning and filtered by
software to separate the differently stained tissue com-
ponents. Assuming homogeneity of staining for each
sample, the means and finally the percentages of areas
corresponding, respectively, to elastic fibers, matrix, and
smooth muscle cells were evaluated. The aortic wall
thickness was calculated as the distance between the in-
ternal and the external elastic lamina. At least five mea-
surements per each aortic fragment were performed us-
ing the same image analysis system.
Biochemical measurements
Biochemical determinations of 4-OH-proline (a
marker of collagen content) and desmosines (desmosine
and isodesmosine, indexes of protein cross-links gener-
ally referred to elastin) were performed directly on whole
tissue hydrolysates. Frozen aortic samples were freeze-
dried for 48 h in a Lyovac GT2 lyophilizer (LeyBold
Technologies, Milan, Italy) and chemically hydrolyzed
with 6 N HCl for 72 h at 110°C in sealed glass tubes.
To determine 4-OH-proline concentration, aorta hy-
drolysates were evaporated under vacuum at 45°C, the
residues dissolved in 0.003 N HCl and applied to a
column with analytical grade cation-exchange resins
(52–100 mesh H+; BDH, Milan, Italy). The column
was then washed with water and eluted with 2 N NH3.
After evaporation under a vacuum at 45°C, the eluates
were resuspended in water, buffered with 0.1 M borate
(pH 9.1), and oxidized with a chloramine T solution
(19). Oxidation was stopped with Ehrlich reactive.
After incubation in a shaking thermostatic bath at
65°C and subsequent cooling, samples were extracted in
6 M of NaOH and toluene. The water-insoluble phase
was added to 0.03 N HCl and centrifuged (3,000 rpm).
The concentration of 4-OH-proline was measured at 550
nm wavelength in a Beckmann (Milan, Italy) DU 650
spectrophotometer.
Desmosine and isodesmosine cross-links in aortic hy-
drolysates were determined by high-performance liquid
chromatography (20). Dried hydrolysates of aorta were
resuspended in 6 N HCl, acetic acid, and n-butanol 1:1:4
(solution A) and applied to a cellulose column that was
then washed with 40 ml of acetic acid, water, and n-
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butane 1.1:1:4 (solution B) and eluted with water. The
eluates were finally evaporated under vacuum and de-
rivatizated solutions were obtained by sequentially add-
ing 410 l of 0.4-M borate buffer, pH 9, dissolved in
methanol (8:2); 30 l of internal standard (acetyl-l-
lysine; 4-dimethyl-amino-azo-benzene, 4 sulfonyl-
chloride); 20 l of 0.1 M KCN in water; and 40 l of
30-mM 2,3-naphthalen-dicarboxy-aldehyde in methanol.
The derivatizated solutions were shaken and injected in
the high-performance liquid chromatography apparatus
(Beckmann System Gold, Programmable Solvent Mod-
ule 126 and Diode Array Detector Module 168) equipped
with a precolumn LiChrospher 60 RP-Select 5 mm (Li-
ChroCart) and a Supelcosil LC-18-DB column (15-cm
length, 4.6-mm thickness, 3-mm particle size, Supelco,
Milan, Italy). The mobile phase was composed of two
different solvents: solvent A, consisting of 0.005 M of
tribasic sodium citrate and 0.05 M of sodium perchlorate,
and solvent B, composed of 0.05 M of sodium perchlor-
ate in methanol. The flow of solvent A was set to 0.55
ml/min and mixed in different percentages with solvent
B. The samples were analyzed with a deuterium lamp
(D2 Beckmann) at 420 nm wavelength.
Statistical methods
Results from arterial blood pressure measurements
obtained in the 3 weeks preceding the killing were av-
eraged and analyzed by means of one-way analysis of
variance (ANOVA) followed by Dunnett test. Sodium
intake and excretion were analyzed by ANOVA for re-
peated measures and post hoc Games-Howell test for
multiple comparisons. Biochemical and histomorpho-
metric data were analyzed by one-way ANOVA and
Games-Howell test. Results are presented as mean ± SD,
assuming p < 0.05 as the level of significant difference.
Statistical analysis was performed using the Statistical
Package for the Social Sciences, version 8.0 (Chicago,
IL, U.S.A., 1998).
RESULTS
Treatment effects on hypertension
As reported in the literature, SHRsp maintained on a
high-sodium diet presented a higher mortality (half-life
 14 weeks of age, 6 weeks of treatment) (17). Data on
survival, body weight gain, fluid intake, diuresis, blood
pressure (measured by the tail-cuff method), and organ
lesions in delapril- and indapamide-treated SHRsp have
already been reported (14,16). Therefore, in the present
paper we reevaluated the changes in blood pressure lev-
els by performing an intergroup/experiment comparison
at the time the animals were killed (Table 1). According
to this analysis, delapril and indapamide combination at
the highest doses effectively controlled hypertension,
resulting in significantly (p < 0.01) lower blood pres-
sure values (approximately 60 mm Hg less) than values
in controls. Instead, the other treatments proved to be
ineffective.
Effects of delapril and indapamide combined
treatments on sodium balance
In experiment 2, we examined the effects of delapril
and indapamide combination on sodium intake and ex-
cretion, to monitor the degree of salt loading in relation
to hypertension and lesion appearance. Data on differ-
ences in sodium excretion before and after the beginning
of salt loading are known (16). As illustrated in Fig. 1,
sodium intake steeply increased in rats treated with de-
lapril 1.5 mg/kg/d + indapamide 0.125 mg/kg/d from the
9th week of treatment onward, accompanied by similar
changes in natriuresis. In these animals sodium intake,
but not sodium excretion, declined in the last 4 weeks,
suggesting a progressive reduction in sodium balance. In
animals treated with delapril 3 mg/kg/d + indapamide
0.25 mg/kg/d, sodium intake was generally significantly
lower than in rats treated with delapril 6 mg/kg/d + in-
dapamide 0.5 mg/kg/d (Fig. 1A), and slowly declined
after the 3rd week of treatment (when it peaked) up to the
TABLE 1.
Effect of delapril, indapamide and their combinations on arterial blood pressure levels in SHRsp
Treatments Sal De12 In1 De12ln1 De6ln0.5 De3ln0.25 De1.5ln0.125
Age (weeks) 14 33 33 30 51 51 25
Blood Pressure (mm Hg) 273 ± 22 270 ± 22 265 ± 13 228 ± 8** 261 ± 20 276 ± 21 289 ± 7
Blood pressure values of the last three weeks before killing were averaged and compared.
De12, delapril 12 mg/kg; In1, indapamide 1 mg/kg; De12In1, delapril12 mg/kg + indapamide 1 mg/kg;
De1.5In0.125, delapril 1.5 mg/kg + indapamide 0.125 mg/kg; De3In0.25, delapril 3 mg/kg + indapamide 0.25
mg/kg; De6In0.5, delapril 6 mg/kg + indapamide 0.5 mg/kg; Sal, saline-treated SHRsp.
*p < 0.05 and **p < 0.01 vs saline-treated SHRsp (control group), Dunnett test.
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end of the experiment. However, sodium excretion was
almost stable in this group (Fig. 1B), suggesting a pro-
gressive decrease in salt-loading efficacy in SHRsp
treated with delapril 3 mg/kg/d + indapamide 0.25
mg/kg/d. After the 3rd week of treatment, sodium intake
declined in rats treated with delapril 6 mg/kg/d + indap-
amide 0.5 mg/kg/d as in animals treated with delapril 3
mg/kg/d + indapamide 0.25 mg/kg/d, but less consis-
tently (Fig. 1A). Natriuresis was significantly higher in
animals treated with delapril 6 mg/kg/d + indapamide 0.5
mg/kg/d than in animals treated with delapril 3 mg/kg/d
+ indapamide 0.25 mg/kg/d in 8 of 44 weeks of the study
(Fig. 1B), but not enough to compensate for differences
found in sodium intake among the two groups.
Biochemical evaluation of extracellular
matrix markers
Drug treatments differently affected the biochemical
composition of the aortic wall (Table 2). In animals
treated with delapril 12 mg/kg/d, highly significant in-
creases in 4-OH-proline (p < 0.01) and desmosine con-
tent (p < 0.05) were observed with respect to the drug-
free salt-loaded group. Significantly increased levels of
4-OH-proline (p < 0.05 versus the drug-free salt-loaded
group) were found also in animals treated with indap-
amide 1 mg/kg/d. By contrast, 4-OH-proline amounts in
animals treated with delapril 12 mg/kg/d + indapamide 1
mg/kg/d were very similar to those found in the drug-free
salt-loaded group and were significantly lower than those
in the other age-matched treatment groups (Table 2).
Desmosine cross-links instead increased significantly
with combined drugs (p < 0.01 versus the drug-free salt-
loaded group) as in the other drug treatment groups.
Histomorphometric findings
In experiment 1, significant effects of the delapril and
indapamide combination on aortic wall remodeling were
observed. As shown in Fig. 2A, vessel wall thickening
was significantly (p < 0.01) lower (about 20% less) in
rats treated with delapril 12 mg/kg/d + indapamide 1
mg/kg/d than in animals treated with delapril 12 mg/kg/d
or indapamide 1 mg/kg/d. At histomorphometry, the de-
lapril 12 mg/kg/d and indapamide 1 mg/kg/d treatment
groups had a significantly (p < 0.01 versus rats treated
with delapril 12 mg/kg/d + indapamide 1 mg/kg/d) in-
creased matrix density (about +40%). Conversely, elastic
FIG. 1. Sodium intake and renal excretion in stroke-prone spontaneously hypertensive rats (SHRsp) treated with different delapril and
indapamide combination doses. A. Sodium intake (mEq/d) was deduced from fluid intake (1% sodium chloride solution) and normalized
by body weight (g). B. Sodium excretion measured after a daily (24-h) urine collection. De1.5In0.125 = delapril 1.5 + indapamide 0.125
mg/kg; De3In0.25 = delapril 3 mg/kg + indapamide 0.25 mg/kg; De6In0.5 = delapril 6 mg/kg + indapamide 0.5 mg/kg; Sal = saline. *p <
0.05 versus 1 treatment group, Games-Howell test for multiple comparisons.
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fiber density decreased (about −25%) with respect to rats
treated with delapril 12 m/gk/g + indapamide 1 mg/kg/d
(Fig. 3A).
In experiment 2, no differences were observed when
considering aortic wall thickness (Fig. 2B), in spite of the
age differences between animals treated with delapril 1.5
mg/kg/d + indapamide 0.125 mg/kg/d and the other
groups (Table 1). By contrast, well-defined dose-related
changes in matrix density were appreciated on histomor-
phometry (Fig. 3B). In fact, matrix levels were signifi-
cantly (p < 0.05 versus all other groups) higher in ani-
mals treated with delapril 1.5 mg/kg/d + indapamide
FIG. 2. Changes in aortic wall thickness in saline-treated (A) or drug-treated (B) stroke-prone spontaneously hypertensive rats (SHRsp).
Means represent the distance between internal and external elastic lamina. Control rats (Sal) were 14 weeks old. Drug-treated rats were
instead 33 (De12, In1), 30 (De12In1), 51 (De6In0.5, De3In0.25), and 25 (De1.5In0.125) weeks old. Sal = saline; De12 = delapril 12 mg/kg;
De1.5In0.125 = delapril 1.5 mg/kg + indapamide 0.125 mg/kg; De3In0.25 = delapril 3 mg/kg + indapamide 0.25 mg/kg; De6In0.5 = delapril
6 mg/kg + indapamide 0.5 mg/kg; De12In1 = delapril 12 mg/kg + indapamide 1 mg/kg; In1 = indapamide 1 mg/kg. **p < 0.01 versus
De12In1-treated SHRsp; #p < 0.05 versus Sal-treated SHRsp, Games-Howell test for multiple comparisons.
TABLE 2.
Changes in the biochemical composition of the aortic wall evaluated by
measuring 4-OH-proline, desmosine and isodesmosine (indicated as
desmosines) levels
Treatments Sal De12 In1 De12In1
n 6 6 4 4
4-OH-proline 11.09 ± 4.30 24.51 ± 4.18**## 21.74 ± 4.10*# 7.99 ± 0.97
Desmosines 0.38 ± 0.09 0.91 ± 0.21* 0.70 ± 0.20 0.59 ± 0.02**
Control rats (Sal) were 14 weeks-old, drug-treated rats were instead 33 (De12, In1) and
30 (De12In1) weeks-old. All values are expressed as g/mg of aortic dry defatted weight.
De12, delapril 12 mg/kg; In1, indapamide 1 mg/kg; De12In1, delapril12 mg/kg +
indapamide 1 mg/kg; Sal, saline.
*p < 0.05, **p < 0.01 vs. Sal SHRsp; #p < 0.05, ##p < 0.01 vs. De12In1 SHRsp,
Games-Howell test for multiple comparisons.
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0.125 mg/kg/d and decreased progressively with increas-
ing combination doses. Elastic fiber density was also
significantly (p < 0.05) higher in animals treated with
delapril 1.5 mg/kg/d + indapamide 0.125 mg/kg/d than in
the other treatment groups, probably because this group
was composed of younger animals (Table 1). Cell den-
sity instead was significantly (p < 0.01) lower in animals
treated with delapril 1.5 mg/kg/d + indapamide 0.125
mg/kg/d as compared with animals treated with delapril
3 mg/kg/d + indapamide 0.25 mg/kg/d and those treated
with delapril 6 mg/kg/d + indapamide 0.5 mg/kg/d. A
significant (p < 0.01) difference in matrix and cell den-
sity was also found between the delapril 3 mg/kg/d +
indapamide 0.25 mg/kg/d and delapril 6 mg/kg/d + in-
dapamide 0.125 mg/kg/d treatment groups.
Ultrastructural analysis of aortic remodeling
Drug treatment effects on SHRsp aorta ultrastructural
features were analyzed in animals treated with scaled
doses of the combination. In Fig. 4, a combination of
drug- and age-dependent effects on aortic wall remodel-
ing is illustrated. In rats treated with delapril 6 mg/kg/d
+ indapamide 0.5 mg/kg/d (Fig. 4A) and rats treated with
delapril 3 mg/kg/d + indapamide 0.25 mg/kg/d (Fig. 4B)
that survived until age 51 weeks, a notable thinning of
elastic laminae was observed as compared with 25-week-
old animals treated with delapril 1.5 mg/kg/d + indap-
amide 0.125 mg/kg/d (Fig. 4C). However, the elastic
laminae presented a better morphology in the animals
treated with highest doses of drug combination, because
in those receiving delapril 1.5 mg/kg/d + indapamide
0.125 mg/kg/d they were highly irregularly shaped. The
other components of the extracellular matrix seemed to
be increased to a greater extent in younger (delapril 1.5
mg/kg/d + indapamide 0.125 mg/kg/d group) than older
(delapril 3 mg/kg/d + indapamide 0.25 mg/kg/d and de-
lapril 6 mg/kg/d + indapamide 0.5 mg/kg/d combina-
tion-treated rats, suggesting a failure of the lowest doses
to protect the aortic wall. In addition, signs of cell atro-
phy were visible in rats treated with delapril 1.5 mg/kg/d
+ indapamide 0.125 mg/kg/d. By contrast, smooth
muscle cells were apparently normal in animals treated
with the highest drug combination doses. Thus, differ-
ences in matrix and relative cell densities found at his-
tomorphometry after combined drug treatment (Fig. 3B)
could be related to a higher matrix deposition and cell
atrophy in younger (delapril 1.5 mg/kg/d + indapamide
0.125 mg/kg/d) as compared with older (delapril 3
mg/kg/d + indapamide 0.5 mg/kg/d and delapril 6
mg/kg/d + indapamide 0.5 mg/kg/d) SHRsp.
FIG. 3. Histomorphometry of changes in the aortic wall composition of stroke-prone spontaneously hypertensive rats (SHRsp) following
saline (A) or drug (B) treatments. Sal = saline; De12 = delapril 12 mg/kg; De1.5In0.125 = delapril 1.5 + indapamide 0.125 mg/kg;
De3In0.25 = delapril 3 mg/kg + indapamide 0.25 mg/kg; De6In0.5 = delapril 6 mg/kg + indapamide 0.5 mg/kg; De12In1 = delapril 12 mg/kg
+ indapamide 1 mg/kg; In1 = indapamide 1 mg/kg. A. *p < 0.05, **p < 0.01 versus De12In1-treated SHRsp. B. *p < 0.05, **p < 0.01 versus
De6In0.5-treated SHRsp; #p < 0.05, ##p < 0.01 versus De3In0.25-treated SHRsp, Games-Howell test for multiple comparisons.
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DISCUSSION
We analyzed the effects of chronic anti-hypertensive
drug treatment on the thoracic aortic wall of salt-loaded
SHRsp. To our knowledge, this is the only study follow-
ing SHRsp aortic alterations in the long term (approxi-
mately 1 year in combined drug treatments); thus it can-
not be compared with similar studies that showed
beneficial effects of ACE inhibitors and thiazides in the
short term (11,21–24). Due to salt-loading procedure, our
study was limited by the age differences occurring be-
tween the groups with high (drug-free salt-loaded rats
and rats treated with delapril 1.5 mg/kg/d + indapamide
0.125 mg/kg/d), medium (delapril 12 mg/kg/d-, indap-
amide 1 mg/kg/d-, and delapril 12 mg/kg/d + indapamide
1 mg/kg/d-treated rats), and low (delapril 3 mg/kg/d +
indapamide 0.25 mg/kg/d- and delapril 6 mg/kg/d + in-
dapamide 0.5 mg/kg/d-treated rats) mortality rate. Ac-
cordingly, differences in elastin and cell density between
the younger (salt loaded and delapril 1.5 mg/kg/d + in-
dapamide 0.125 mg/kg/d) and the other older groups of
treatment might be explained by the aging processes of
the aortic wall (25). Moreover, the lowest values of cell
density were found in rats treated with delapril 1.5
mg/kg/d + indapamide 0.125 mg/kg/d, supporting the
hypothesis of a larger damage to smooth muscle cells
caused by persistence of very high blood pressure levels
in this group as compared with controls (16). This hy-
pothesis was further strengthened by ultrastructural
analysis that demonstrated atrophic smooth muscle cells
in this treatment group.
Conversely, we were able to demonstrate an age-
independent effect of drug treatments. Indeed, aortic
thickness in 30-week-old combination-treated rats (del-
april 12 mg/kg/d + indapamide 1 mg/kg/d) was found to
be comparable to that of 14-week-old controls. This find-
ing suggests that combination treatment was able to an-
tagonize aortic wall thickening that occurs in aged
SHRsp (Baccarani Contri et al., in preparation). By con-
trast, delapril or indapamide administered separately
both failed to preserve aortic size. These findings were
corroborated by histomorphometric data showing signifi-
cantly lower matrix levels in combination-treated rats, in
which a clear dose-response effect with scaled doses of
the combination was also found. These semiquantitative
results, obtained by calculating the relative density of
each component as percent of tunica media area, were in
line with the biochemical findings that demonstrated a
significantly lower 4-OH-proline concentration in com-
bination-treated rats. Desmosine levels were instead
comparable between the various drug treatment groups.
This is in contrast with histomorphometric findings that
FIG. 4. Electron microscopy of the aortic wall from SHRsp
treated with different delapril and indapamide combination doses.
A portion of tunica media between two elastic laminae is shown
for delapril 6 mg/kg + indapamide 0.5 mg/kg (A), delapril 3 mg/kg
+ indapamide 0.25 mg/kg (B), and delapril 1.5 + indapamide
0.125 mg/kg (C) treatments. The arrows point to smooth muscle
cells. C, collagen; EL, elastic lamina; SMC, smooth muscle cell.
Scale bars = 2 µm.
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show a significantly higher elastin density in combina-
tion as compared with indapamide-treated SHRsp. As
desmosines are markers of mature cross-linked elastin
(20), this result suggests an enhanced production or de-
creased processing of immature elastin in combination-
treated animals.
In humans as in hypertensive animals, stiffening of
large vessels can increase systolic blood pressure and
pulse pressure (26,27), leading to heart hypertrophy and
favoring cardiovascular mortality (1,9,26,27). Notably,
we found that delapril and indapamide combined treat-
ments, although ineffective in lowering arterial blood
pressure values in SHRsp, were able to antagonize aortic
wall thickening due to increased matrix synthesis, as
evaluated by histomorphometry, biochemistry, and elec-
tron microscopy. Blood pressure levels were substan-
tially stabilized at the highest combination doses, but no
effects on blood pressure were observed with decreasing
doses that maintained comparable protective effects on
the aortic wall. These findings suggest that the drugs we
used possess anti-fibrotic properties that are not related
to their anti-hypertensive effects. Although ACE inhibi-
tors are known to prevent fibrosis in the SHR aortic wall
(3), indapamide administered at a dose of 3 mg/kg was
found to be ineffective in salt-loaded SHRsp (21). Our
results demonstrate that indapamide administered at 1
mg/kg has effects equivalent to those found with delapril
administered at 12 mg/kg on matrix deposition in the
aortic wall and that a substantial improvement could be
achieved by combining them. Similar findings were also
obtained in the aortic wall of SHRs maintained on a
normal diet by combining perindopril and indapamide
treatment, but in this case a significant difference in
blood pressure levels between control and drug-treated
rats was found at any dose used (22). Thus, to our knowl-
edge this is the first time that these beneficial effects of
the ACE inhibitor and thiazide combination have been
shown to be independent of anti-hypertensive properties.
Vessel wall fibrosis has been shown to be limited by
ACE inhibitors via a direct antagonism of angiotensin II
synthesis (3,23). In fact, locally produced angiotensin II
controls the synthesis of collagen in the arterial wall
directly or by inducing autocrine/paracrine mediators,
such as transforming growth factor (TGF)-1 (4). Di-
etary sodium chloride is capable of inducing TGF-1
and stimulating kinin synthesis, affecting the structure of
arterial blood vessels (11). These effects could explain
why ACE inhibitors were found to lose their protective
properties in the presence of salt loading (12,13). We
previously observed that delapril 12 mg/kg combined
with indapamide 1 mg/kg, i.e., the highest dose tested, is
capable of stimulating diuresis, suggesting the possibility
that the negative effects of salt loading on ACE inhibi-
tion and vessel wall could be prevented by increased
sodium excretion (14). This effect could explain the lim-
ited fibrosis found in the aortic wall of animals treated
with the highest doses of the combination. To challenge
this hypothesis, we analyzed the effects of scaled doses
of the combined drugs on sodium excretion and aortic
wall fibrosis. We found that a half-dose of the highest
dose combination maintained the protective effects on
the aortic wall intact but lacked diuretic properties. A
further half-dose of delapril and indapamide combination
showed attenuated but still evident vascular protective
effects. Conversely, we did not observe consistent dif-
ferences in sodium balance or arterial blood pressure
between the groups receiving these scaled drug doses.
Only in rats treated with very low combination doses (1
of 8 of the highest doses) were no protective effects
found on aortic wall changes. However, in this last case
the sodium balance was greatly affected, possibly in re-
lation to renal damage (16).
We cannot clearly explain the synergistic effects of the
drug combination. Indapamide has been shown to be a
potent anti-oxidant (28), to antagonize calcium influx in
smooth muscle cells (29), and to modulate nitric oxide
synthesis in the SHR aorta when combined with ACE
inhibitors (22). These data suggest that indapamide can
directly affect vessel wall properties. Recently, Pickkers
et al. (30,31) showed that thiazide diuretics can be accu-
mulated by vascular smooth muscle cells reaching intra-
cellular concentrations able to inhibit carbonic anhy-
drase, thus shifting intracellular pH to alkaline values. In
turn, intracellular alkalinization can activate large-
conductance calcium-activated potassium channels, pro-
ducing vasorelaxant effects. Indeed, this effect could be
synergistic with that of ACE inhibitors that, by lowering
angiotensin II synthesis, decrease the activation of an-
giotensin II type 1 receptors and smooth muscle cell
contraction (32). Interestingly, thiazide effects on car-
bonic anhydrase could take place at clinically relevant
concentrations, explaining why their anti-hypertensive
properties are independent of diuresis stimulation. Thus,
it might prove worthy to investigate whether such direct
modulation of smooth muscle cell activity is involved in
the anti-hypertrophic/anti-fibrotic effects of indapamide
demonstrated for the heart (33,34) and large arteries (35)
and the possible interactions with ACE inhibitor effects.
In conclusion, we provide evidence that delapril
and indapamide synergize to protect the aortic wall in
extremely adverse conditions, such as those seen in
the SHRsp genetic model of hypertension (in which
blood vessels constitutively tend to develop pathologic
changes) further strained by a sodium chloride–enriched
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diet. These findings encourage the reevaluation of di-
uretic and ACE inhibitor combinations as possible first-
line treatment, aimed at preserving large vessels from the
pathologic changes occurring in long-term hypertension.
Interestingly, when patients manifest a poor compliance
to aggressive anti-hypertensive treatments (36), the use
of ACE inhibitor and thiazide diuretic combinations at
lower doses can nonetheless be advantageous, because
their cardiovascular protective properties appear to be
largely independent of blood pressure–lowering and di-
uretic effects. Moreover, the growing evidence on direct
vascular effects of ACE inhibitors and diuretics suggests
that their clinical use should also be investigated in vas-
cular diseases unrelated to hypertension.
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